Bevacizumab + nivolumab + rucaparib for fallopian tube neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Aug 2016: Trial registered, NCT02873962
  2. 10 Nov 2016: Trial started, NCT02873962

The trials

NCT02873962: A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

State
Under way
Phase
Phase 2
People
72 taking part
Started
10 Nov 2016
Primary completion
Feb 2025
Arms
Cohort 2: Nivolumab with Bevacizumab and Rucaparib, Cohort 3: Nivolumab with Bevacizumab and Rucaparib
Results
Posted on the registry
  1. 22 Aug 2016: Trial registered
  2. 10 Nov 2016: Trial started
  3. 1 Apr 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.